Compliance with the Global CAPA program is mandated by several regulations including 21 CFR Part 211.180/192 for records and reports of drug product failure investigations, 21 CFR Part 820.100 for Quality System Regulation for Corrective and Preventive Action, and EU GMP Volume 4, Chapter 1 for Quality Management.